Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Richard H. Chapman"'
Autor:
Praveen Thokala, Matt Stevenson, Varun M. Kumar, Shijie Ren, Alexandra G. Ellis, Richard H. Chapman
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-12 (2020)
Abstract Background Patients with infantile-onset spinal muscular atrophy (SMA), a rare, genetic neuromuscular disease, do not achieve key motor function milestones (e.g., sitting) and have short life expectancy in the absence of treatment. Nusinerse
Externí odkaz:
https://doaj.org/article/871c9a6b1b5d482581dc4deb1ae23c78
Autor:
Linong Ji, Arthi Chandran, Timothy J. Inocencio, Zilin Sun, Qifu Li, Guijun Qin, Zheng Wei, Stefan DiMario, Richard H. Chapman
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Pen needles are an important component of insulin delivery among patients with diabetes, but are not universally covered in China. We compared clinical and economic characteristics of insulin-dependent patients in China who have s
Externí odkaz:
https://doaj.org/article/b2292c4aa451496aa7bbb166fc3cd792
Autor:
Zachary Predmore, Emily K Chen, Thomas W Concannon, Suzanne Schrandt, Susan J Bartlett, Clifton O Bingham, Richard Z Xie, Richard H Chapman, Lori Frank
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 5 (2023)
Aim: We developed the Patient-Engaged Health Technology Assessment strategy for survey-based goal collection from patients to yield patient-important outcomes suitable for use in multi-criteria decision analysis. Methods: Rheumatoid arthritis patie
Externí odkaz:
https://doaj.org/article/13685de71cd3448fbf948c34a0679059
Autor:
Mrinmayee, Joshi, Steven J, Atlas, Molly, Beinfeld, Richard H, Chapman, David M, Rind, Steven D, Pearson, Daniel R, Touchette
Publikováno v:
Value in Health. 26:823-832
Nadofaragene firadenovec is a gene therapy for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) undergoing FDA review. Pembrolizumab is approved for treating BCG-unresponsive NMIBC patients with carcinoma in-situ (CIS). We evaluated the co
Autor:
Susan dosReis, Laura M. Bozzi, Beverly Butler, Richard Z. Xie, Richard H. Chapman, Jennifer Bright, Erica Malik, Julia F. Slejko
Publikováno v:
The Patient - Patient-Centered Outcomes Research. 16:57-66
Autor:
Olena Mandrik, James Fotheringham, Shijie Ren, Jeffrey A. Tice, Richard H. Chapman, Matthew D. Stevenson, Steven D. Pearson, Serina Herron-Smith, Foluso Agboola, Praveen Thokala
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives: Despite existing therapies, people with lupus nephritis progress to kidney failure and have reduced life expectancy. Belimumab and voclosporin are two new disease-modifying therapies recently approved for the treatment of l
Publikováno v:
Value in Health. 24:839-845
Objectives To evaluate alternative methods to calculate and/or attribute economic surplus in the cost-effectiveness analysis of single or short-term therapies. Methods We performed a systematic literature review of articles describing alternative met
Autor:
Jürgen Wolf, Jacoline C. Bouvy, Oriol Sola-Morales, Richard H. Chapman, Andrew Briggs, Carsten Bokemeyer, Jennifer G. Gaultney, Alexander J Upton, Stacey Kowal
Publikováno v:
Applied Health Economics and Health Policy. 19:625-634
The arrival of precision oncology is challenging the evidence standards under which technologies are evaluated for regulatory approval as well as for health technology assessment (HTA) purposes. Several key concepts are discussed to highlight the sou
Autor:
Steven D. Pearson, Ryan N. Hansen, Katherine Fazioli, David Rind, Richard H. Chapman, Gregory F. Guzauskas
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 27:455-468
BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control in people with type 2 diabetes mellitus (T2DM). While oral semaglutide is not in
Publikováno v:
Applied Health Economics and Health Policy. 18:601-604